CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Treace Medical Concepts, Inc. - TMCI CFD

12.98
5.19%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.08
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Treace Medical Concepts Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 12.34
Open* 12.47
1-Year Change* -49.68%
Day's Range* 12.44 - 13.11
52 wk Range 5.27-27.97
Average Volume (10 days) 915.26K
Average Volume (3 months) 22.09M
Market Cap 783.28M
P/E Ratio -100.00K
Shares Outstanding 61.68M
Revenue 174.68M
EPS -0.79
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 27, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 12.34 0.81 7.03% 11.53 12.39 11.49
Mar 26, 2024 11.45 -0.29 -2.47% 11.74 11.86 11.41
Mar 25, 2024 11.81 -0.34 -2.80% 12.15 12.25 11.79
Mar 22, 2024 12.14 -0.05 -0.41% 12.19 12.52 11.96
Mar 21, 2024 12.53 -0.03 -0.24% 12.56 12.79 12.49
Mar 20, 2024 12.47 0.41 3.40% 12.06 12.63 11.99
Mar 19, 2024 12.11 0.46 3.95% 11.65 12.22 11.65
Mar 18, 2024 11.98 0.05 0.42% 11.93 12.27 11.56
Mar 15, 2024 11.86 0.07 0.59% 11.79 12.26 11.72
Mar 14, 2024 12.17 -0.13 -1.06% 12.30 12.30 11.65
Mar 13, 2024 12.28 0.10 0.82% 12.18 12.48 12.18
Mar 12, 2024 12.33 -0.41 -3.22% 12.74 12.74 12.33
Mar 11, 2024 12.79 -0.08 -0.62% 12.87 13.10 12.63
Mar 8, 2024 13.10 -0.14 -1.06% 13.24 13.65 12.97
Mar 7, 2024 13.22 -0.04 -0.30% 13.26 13.72 13.20
Mar 6, 2024 13.23 0.12 0.92% 13.11 13.28 12.97
Mar 5, 2024 13.11 -0.37 -2.74% 13.48 13.66 13.11
Mar 4, 2024 13.69 0.41 3.09% 13.28 13.76 13.12
Mar 1, 2024 13.37 0.20 1.52% 13.17 13.71 13.16
Feb 29, 2024 13.39 -0.14 -1.03% 13.53 13.94 13.19

Treace Medical Concepts, Inc. Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Treace Medical Concepts Inc Earnings Release
Q1 2024 Treace Medical Concepts Inc Earnings Release

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

15:00

Country

US

Event

Treace Medical Concepts Inc Annual Shareholders Meeting
Treace Medical Concepts Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 141.838 94.419 57.365 39.416
Revenue 141.838 94.419 57.365 39.416
Cost of Revenue, Total 27.523 17.826 12.47 7.631
Gross Profit 114.315 76.593 44.895 31.785
Total Operating Expense 181.465 110.929 56.51 42.951
Selling/General/Admin. Expenses, Total 135.575 82.899 38.193 30.25
Research & Development 13.584 10.204 5.847 5.07
Operating Income -39.627 -16.51 0.855 -3.535
Interest Income (Expense), Net Non-Operating -3.188 -4.042 -4.523 -0.73
Net Income Before Taxes -42.815 -20.552 -3.668 -4.265
Net Income After Taxes -42.815 -20.552 -3.668 -4.265
Net Income Before Extra. Items -42.815 -20.552 -3.668 -4.265
Net Income -42.815 -20.552 -3.668 -4.265
Total Adjustments to Net Income 0 -0.196 -0.64 -0.64
Income Available to Common Excl. Extra. Items -42.815 -20.748 -4.308 -4.905
Income Available to Common Incl. Extra. Items -42.815 -20.748 -4.308 -4.905
Diluted Net Income -42.815 -20.748 -4.308 -4.905
Diluted Weighted Average Shares 55.2768 48.4157 50.4628 50.4628
Diluted EPS Excluding Extraordinary Items -0.77456 -0.42854 -0.08537 -0.0972
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.68803 -0.42854 -0.08537 -0.0972
Unusual Expense (Income) 4.783
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 41.953 42.195 49.769 33.055 29.967
Revenue 41.953 42.195 49.769 33.055 29.967
Cost of Revenue, Total 7.675 8.039 9.742 6.624 5.291
Gross Profit 34.278 34.156 40.027 26.431 24.676
Total Operating Expense 55.005 55.971 53.566 44.373 46.383
Selling/General/Admin. Expenses, Total 43.804 44.52 39.775 33.95 33.625
Research & Development 3.526 3.412 3.749 3.799 2.984
Operating Income -13.052 -13.776 -3.797 -11.318 -16.416
Interest Income (Expense), Net Non-Operating 0.686 0.194 -0.615 -0.815 -0.815
Net Income Before Taxes -12.271 -13.454 -4.412 -12.133 -17.234
Net Income After Taxes -12.271 -13.454 -4.412 -12.133 -17.234
Net Income Before Extra. Items -12.271 -13.454 -4.412 -12.133 -17.234
Net Income -12.271 -13.454 -4.412 -12.133 -17.234
Total Adjustments to Net Income 0 0
Income Available to Common Excl. Extra. Items -12.271 -13.454 -4.412 -12.133 -17.234
Income Available to Common Incl. Extra. Items -12.271 -13.454 -4.412 -12.133 -17.234
Diluted Net Income -12.271 -13.454 -4.412 -12.133 -17.234
Diluted Weighted Average Shares 61.3825 58.7238 55.5356 55.4292 55.3083
Diluted EPS Excluding Extraordinary Items -0.19991 -0.22911 -0.07944 -0.21889 -0.3116
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.19991 -0.22911 -0.07404 -0.21889 -0.23054
Unusual Expense (Income) 0 0.3 0 4.483
Other, Net 0.095 0.128 -0.003
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 133.402 137.972 40.978 28.57
Cash and Short Term Investments 81.252 105.833 18.079 12.139
Cash & Equivalents 16.211 105.833 18.079 12.139
Total Receivables, Net 29.196 18.568 14.486 10.411
Accounts Receivable - Trade, Net 29.196 18.568 14.486 10.411
Total Inventory 19.33 10.561 7.82 5.562
Prepaid Expenses 3.624 3.01 0.594 0.458
Total Assets 159.024 140.821 41.807 29.716
Property/Plant/Equipment, Total - Net 25.476 2.849 0.829 1.146
Property/Plant/Equipment, Total - Gross 29.739 5.588 3.465 2.787
Accumulated Depreciation, Total -4.263 -2.739 -2.636 -1.641
Total Current Liabilities 30.245 18.21 11.598 7.332
Accounts Payable 8.668 4.056 2.265 0.931
Accrued Expenses 21.577 14.154 7.544 6.401
Notes Payable/Short Term Debt 0 0 1.788 0
Total Liabilities 98.495 47.748 41.031 26.555
Total Long Term Debt 52.711 29.365 29.189 19.223
Long Term Debt 52.711 29.365 29.189 19.223
Other Liabilities, Total 15.539 0.173 0.244 0
Total Equity 60.529 93.073 0.776 3.161
Redeemable Preferred Stock 0 0 7.935 7.935
Common Stock 0.055 0.045 0.028 0.028
Additional Paid-In Capital 145.221 134.933 14.166 12.884
Retained Earnings (Accumulated Deficit) -84.72 -41.905 -21.353 -17.686
Total Liabilities & Shareholders’ Equity 159.024 140.821 41.807 29.716
Total Common Shares Outstanding 55.6282 54.1811 50.4628 50.4628
Other Current Assets, Total -0.001
Other Current Liabilities, Total 0.001
Cash 3.262
Short Term Investments 61.779
Other Long Term Assets, Total 0.146
Other Equity, Total -0.027
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 187.142 198.096 223.133 133.402 127.902
Cash and Short Term Investments 122.163 139.479 170.662 81.252 88.546
Cash & Equivalents 2.738 9.084 26.147 16.211 85.839
Total Receivables, Net 24.996 27.232 25.365 29.196 18.548
Accounts Receivable - Trade, Net 24.996 27.232 25.365 29.196 18.548
Total Inventory 29.312 26.101 22.519 19.33 16.794
Prepaid Expenses 10.671 5.284 4.587 3.624 4.014
Total Assets 240.36 249.643 249.17 159.024 156.443
Property/Plant/Equipment, Total - Net 30.995 29.086 25.822 25.476 28.395
Property/Plant/Equipment, Total - Gross 38.225 35.08 30.898 29.739 31.926
Accumulated Depreciation, Total -7.23 -5.994 -5.076 -4.263 -3.531
Total Current Liabilities 33.154 30.022 23.296 30.245 22.58
Accounts Payable 8.68 8.146 5.076 8.668 7.881
Accrued Expenses 20.462 19.062 17.51 21.577 14.699
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 102.5 99.684 91.553 98.495 94.242
Total Long Term Debt 52.934 52.859 52.785 52.711 52.636
Long Term Debt 52.934 52.859 52.785 52.711 52.636
Other Liabilities, Total 16.412 16.803 15.472 15.539 19.026
Total Equity 137.86 149.959 157.617 60.529 62.201
Redeemable Preferred Stock 0 0 0
Common Stock 0.062 0.062 0.061 0.055 0.046
Additional Paid-In Capital 265.912 260.561 255.786 145.221 142.463
Retained Earnings (Accumulated Deficit) -127.966 -110.445 -98.174 -84.72 -80.308
Total Liabilities & Shareholders’ Equity 240.36 249.643 249.17 159.024 156.443
Total Common Shares Outstanding 61.6069 61.5284 61.2807 55.6282 55.4992
Cash 4.54 2.951 3.466 3.262 2.707
Other Long Term Assets, Total 0.146 0.146 0.215 0.146 0.146
Short Term Investments 114.885 127.444 141.049 61.779
Other Equity, Total -0.148 -0.219 -0.056 -0.027
Other Current Liabilities, Total 4.012 2.814 0.71
Goodwill, Net 12.815 12.815
Intangibles, Net 9.262 9.5
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -42.815 -20.552 -3.668 -4.265
Cash From Operating Activities -30.648 -17.193 -4.494 -7.673
Cash From Operating Activities 2.133 0.685 1.21 0.793
Non-Cash Items 15.843 4.004 3.282 1.107
Cash Interest Paid 4.398 3.9 1.146 0.739
Changes in Working Capital -5.809 -1.33 -5.318 -5.308
Cash From Investing Activities -76.518 -2.705 -1.069 -1.211
Capital Expenditures -14.838 -2.705 -1.069 -1.211
Cash From Financing Activities 20.806 107.652 11.503 19.739
Financing Cash Flow Items -0.989 0 -0.179 -0.329
Issuance (Retirement) of Stock, Net 2.187 109.44 0.364 0.068
Issuance (Retirement) of Debt, Net 19.608 -1.788 11.318 20
Net Change in Cash -86.36 87.754 5.94 10.855
Other Investing Cash Flow Items, Total -61.68
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -13.454 -42.815 -38.403 -26.27 -9.036
Cash From Operating Activities -17.259 -30.648 -25.29 -17.807 -7.241
Cash From Operating Activities 0.924 2.133 1.216 0.757 0.334
Non-Cash Items 3.845 15.843 11.911 8.7 1.727
Cash Interest Paid 1.285 4.398 3.087 1.897 0.951
Changes in Working Capital -8.574 -5.809 -0.014 -0.994 -0.266
Cash From Investing Activities -80.48 -76.518 -12.506 -6.649 -1.481
Capital Expenditures -1.478 -14.838 -12.506 -6.649 -1.481
Cash From Financing Activities 107.879 20.806 20.509 20.156 1.372
Financing Cash Flow Items -0.989 -0.989 -0.989
Issuance (Retirement) of Stock, Net 107.879 2.187 1.89 1.537 1.372
Issuance (Retirement) of Debt, Net 19.608 19.608 19.608 0
Net Change in Cash 10.14 -86.36 -17.287 -4.3 -7.35
Other Investing Cash Flow Items, Total -79.002 -61.68

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Treace Medical Concepts, Inc. Company profile

About Treace Medical Concepts Inc

Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company. The Company is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The Company's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The Company's brands include Lapiplasty, Fast Grafter and Plantar Python.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Treace Medical Concepts Inc revenues increased 65% to $94.4M. Net loss applicable to common stockholders increased from $4.3M to $20.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales and marketing - Balancing value increase of 79% to $50.2M (expense).

Industry: Medical Equipment

100 Palmetto Park Place
PONTE VEDRA
FLORIDA 32081
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,561.25 Price
+1.380% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+1.650% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading